%0 Journal Article %T Expression of CD133 Cancer Stem Cell Marker in IDH-Mutant and IDH-wildtype (Isocitrate Dehydrogenase) Astrocytoma %J Asian Pacific Journal of Cancer Prevention %I West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter. %Z 1513-7368 %A Sabunga, Olivia Desty %A Kaelan, Cahyono %A Zainuddin, Andi Alfian %A Sungowati, Ni Ketut %A Cangara, Muhammad Husni %A Miskad, Upik %D 2022 %\ 09/01/2022 %V 23 %N 9 %P 3051-3059 %! Expression of CD133 Cancer Stem Cell Marker in IDH-Mutant and IDH-wildtype (Isocitrate Dehydrogenase) Astrocytoma %K IDH1-R132H %K IDH-mutant %K IDH-wildtype %K CD133 %K astrocytoma %R 10.31557/APJCP.2022.23.9.3051 %X Objective: This study evaluated the differences between IDH1-R132H and CD133 expression in different categories of  astrocytoma. Material and methods: This study used a cross-sectional design.  Sixty-seven paraffin embedded block of Diffuse Astrocytoma (DA), Anaplastic Astrocytoma (AA) and Glioblastoma (GB) were assessed using using the monoclonal antibody IDH1-R132H and Rabbit polyclonal antibody CD133. Results: It was found that there was a significant relationship between the expression of IDH1-R132H and CD133 in DA, AA and GB (p<0.001). Astrocytoma with IDH-mutant molecular status will express more markers of cancer stem cell CD133 than IDH-wildtype. Conclusion: The IDH1-R132H and CD133 can provide predictive value on treatment success, disease prognosis, recurrence and can be considered as target combination therapy with chemotherapy. %U https://journal.waocp.org/article_90270_f3c271070823b2e450d03548c3044ad0.pdf